© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
AMCP Nexus
AMCP Nexus 2021: Cate Lockhart of Biologics and Biosimilars Collective Intelligence Consortium Discusses Biosimilars Such as Semglee and the Current Standing of Biosimilars, PBMs
October 20, 2021
Cate Lockhart, Pharm.D., Ph.D., spoke at AMCP Nexus about biosimilars, the insulin biosimilar Semglee and the role of PBMs.
AMCP Nexus 2021: The Diseases Are Rare. The Orphan Drugs Are Not.
October 20, 2021
The growing ranks of FDA-approved orphan drugs for rare diseases have saved and improved many lives. But the high-priced drugs are also a major cost burden.
AMCP Nexus 2021: Jen Norton, VP & Head of U.S. Value & Access at Amgen Talks Biosimilar Trends and What to Expect in the Next Year
October 19, 2021
Jen Norton spoke at AMCP Nexus about biosimilar trends of 2021 and what to expect in the next 12 months
AMCP Nexus 2021: Jane F. Barlow, M.D., M.P.H., MBA, MIT Center for Biomedical Innovation, Addresses Gene, Cell Therapy and Needed Adjustments of High Costs for Payment Models
October 19, 2021
Barlow spoke at AMCP Nexus about gene and cell therapy and about how payment models need to adjust to account for their high initial cost and their durable — in some cases lifetime — effects.
AMCP Nexus 2021: The Atopic Treatment Landscape
October 19, 2021
The tools for formulary management for atopic dermatitis need flexibility to take into account quality-of-life issues and patient access.
AMCP Nexus 2021: Aimee Loucks, Pharm.D., of Kaiser Permanente Washington Talks Metrics That Can Give Providers an Incentive to Address Disparities
October 19, 2021
Loucks, manager of specialty clinical pharmacy programs and formulary at Kaiser Permanente Washington, discusses metrics that might give healthcare providers an incentive to address healthcare disparities and concrete steps that could be taken to turn the talk about addressing healthcare disparities into a reality.
AMCP Nexus 2021: What the Future May Hold for Mavacamten
October 19, 2021
If the new drug is approved, a Mayo Clinic expert on hypertrophic cardiomyopathy sees the new medication as probably being among the second-line choices for patients who don’t respond to beta blockers and calcium channel blockers.
AMCP Nexus 2021: The Disparate Ways of Addressing Health Disparities
October 19, 2021
The first panel discussion of the meeting was a window into the variety of ways that health plans are working to close health disparities.